FDA 483 - Biovectra Inc. - September 12, 2024

An FDA inspection of BIOVECTRA Inc. in Windsor, Nova Scotia, revealed numerous deficiencies in their drug substance manufacturing processes. Key issues included inadequate microbial control, insufficient deviation investigations, and poor adherence to and validation of standard operating procedures. The findings indicate a lack of robust quality systems and controls over critical aspects of drug substance production.